| Research Topics: |
| INDEX |
| MCS 3 |
| PRIME 37 |
| aging 18 |
| brain 25 |
| brainwave 4 |
| cancer 20 |
| climate 1 |
| cognition 12 |
| covid-19 3 |
| crime 4 |
| culture 4 |
| dental 7 |
| diabetes 7 |
| diagnostics 4 |
| disease 2 |
| drugs 5 |
| economy 2 |
| exercise 2 |
| eyes 1 |
| genetics 7 |
| gut 2 |
| heart 11 |
| immune 4 |
| kidneys 2 |
| language 3 |
| lungs 2 |
| metabolism 4 |
| microbiome 4 |
| misc 1 |
| music 1 |
| nutrition 16 |
| obesity 2 |
| pain 6 |
| physical 1 |
| politics 5 |
| pollution 2 |
| practice 2 |
| privacy 2 |
| psychology 12 |
| reproduction 4 |
| rights 1 |
| sleep 5 |
| soc-media |
| stress 1 |
| tech 3 |
| unk |
| vaccine 2 |
| virus 2 |
| war-confl |
|
Scanned: 4202 Evaluated: 821 Selected: 129 |
| BRAIN DRUGS PSYCHOLOGY | ||||||||
Mga25-004 | Elevated suicidal thoughts and behaviors, proximal suicide risk factors, and non-suicidal self-injury among adults reporting symptoms of Cannabinoid Hyperemesis Syndrome: Results from a national survey of US adults | |||||||
| Quote: | Background Cannabinoid hyperemesis syndrome (CHS), a disorder characterized by severe nausea, vomiting, and abdominal pain among heavy cannabis users. We previously showed that CHS symptoms are associated with several behavioral and psychological characteristics linked to psychosocial impairment. | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.02.26.26347185v2 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.02.26.26347185v2.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Brian M. Hicks Blair J. Whittington Amanda M. Price Paula Goldman Mark A. Ilgen, | |||||||
| BRAIN DRUGS PSYCHOLOGY | ||||||||
Mga25-005 | Links between Cannabinoid Hyperemesis Syndrome symptoms and drug use, mental health problems, antisocial behavior, and personality in a national survey of adults in the United States | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.02.26.26347188v2 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.02.26.26347188v2.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Brian M. Hicks Amanda M. Price Blair J. Whittington Paula Goldman Mark A. Ilgen, | |||||||
| BRAIN DRUGS PSYCHOLOGY | ||||||||
Mga25-006 | Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States | |||||||
| Quote: | Results Overall, 2.7 of all respondents and 17.8 of respondents who used cannabis daily reported CHS-like symptoms. Respondents who were younger, female, identified as non-White, had lower income, had lower educational attainment, and endorsed cannabis-related use problems were more likely to be in the CHS symptom group than in the daily cannabis use group. | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.01.25.26344780v2 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.01.25.26344780v2.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Mark A. Ilgen Amanda M. Price Paula Goldman Blair J. Whittington Brian M. Hicks, | |||||||
| DRUGS IMMUNE | ||||||||
Mim25-003 | Macrophage-targeted glucocorticoid prodrug resolves acute inflammation while preserving HPA axis function: mechanistic, preclinical, and Phase II/III clinical evidence | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.06.05.26354839v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.06.05.26354839v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Michael M. Goldberg Orly Weinreb Alec M. Goldberg James I. Goldberg, | |||||||
| PRIME DRUGS PRACTICE | ||||||||
Mph25-005 | The Third Dimension of Pharmacokinetic"Pharmacodynamic Theory: Adaptive Rate Capacity as a Conserved Constraint on Biological Tolerability | |||||||
| Quote: | Pharmacokineticpharmacodynamic theory describes drug action in two dimensions, magnitude and time, yet rate-dependent toxicity recurs across unrelated therapies without a unifying principle. We propose the Human Adaptive Rate Limit (HARL): every physiological system tolerates a maximum velocity of state change | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.06.02.26354717v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.06.02.26354717v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Cornelis H Kleinbloesem Cornelis L Braal, | |||||||
|
Javilk's Research Links for Week 25 Updated 06/27/2026-03:36:32 AM What interests you? What have you found? Tell me! Drop me a note to subscribe or submit something. |